Iza-bren Meets Dual Endpoints in Phase III TNBC
REDMOND, Wash. & PRINCETON, N.J., February 26, 2026 SystImmune, Inc. and Bristol Myers Squibb announced positive interim topline results...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
REDMOND, Wash. & PRINCETON, N.J., February 26, 2026 SystImmune, Inc. and Bristol Myers Squibb announced positive interim topline results...
BRISBANE, CA – November 13, 2025 — Day One Biopharmaceuticals announced a definitive agreement to acquire Mersana Therapeutics in...
Munich, Germany, October 30, 2025 — Tubulis GmbH announced the successful second and final closing of its Series C...
NIJMEGEN, Netherlands and BOSTON, September 9, 2025 — Tagworks Pharmaceuticals has initiated the third dose level in its ongoing...
